Benitec Biopharma (NASDAQ:BNTC) Director Purchases $236,067.36 in Stock

Benitec Biopharma Limited (NASDAQ:BNTC) Director Suvretta Capital Management, L bought 19,542 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were bought at an average cost of $12.08 per share, for a total transaction of $236,067.36. Following the purchase, the director directly owned 9,577,475 shares in the company, valued at approximately $115,695,898. This represents a 0.20% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Suvretta Capital Management, L also recently made the following trade(s):

• On Friday, December 19th, Suvretta Capital Management, L purchased 16,384 shares of Benitec Biopharma stock. The shares were acquired at an average cost of $11.48 per share, with a total value of $188,088.32.
• On Thursday, December 18th, Suvretta Capital Management, L acquired 10,215 shares of Benitec Biopharma stock. The shares were bought at an average price of $11.24 per share, with a total value of $114,816.60.
• On Friday, November 7th, Suvretta Capital Management, L purchased 1,481,481 shares of Benitec Biopharma stock. The shares were purchased at an average price of $13.50 per share, for a total transaction of $19,999,993.50.

Benitec Biopharma Stock Performance

Shares of BNTC stock traded up $0.85 during mid-day trading on Monday, hitting $12.35. The company’s stock had a trading volume of 143,304 shares, compared to its average volume of 237,340. Benitec Biopharma Limited has a 52-week low of $9.70 and a 52-week high of $17.15. The business has a 50-day moving average price of $13.81 and a 200 day moving average price of $13.46. The stock has a market cap of $418.17 million, a price-to-earnings ratio of -10.21 and a beta of 0.20.

Benitec Biopharma (NASDAQ:BNTC) last posted its earnings results on Friday, November 14th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.13. Equities research analysts predict that Benitec Biopharma Limited will post -1.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Benitec Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. bought a new position in shares of Benitec Biopharma in the first quarter worth about $597,000. Infinitum Asset Management LLC boosted its stake in Benitec Biopharma by 435.7% in the 1st quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company’s stock worth $14,636,000 after purchasing an additional 915,000 shares during the period. MYDA Advisors LLC grew its holdings in Benitec Biopharma by 4.0% during the 1st quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company’s stock valued at $677,000 after buying an additional 2,000 shares in the last quarter. AWM Investment Company Inc. grew its holdings in Benitec Biopharma by 35.2% during the 1st quarter. AWM Investment Company Inc. now owns 137,977 shares of the biotechnology company’s stock valued at $1,795,000 after buying an additional 35,950 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new stake in shares of Benitec Biopharma during the second quarter valued at approximately $95,000. 52.19% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on BNTC shares. Wall Street Zen raised shares of Benitec Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Oppenheimer restated an “outperform” rating and issued a $29.00 price objective (down from $35.00) on shares of Benitec Biopharma in a research note on Tuesday, September 16th. Zacks Research upgraded Benitec Biopharma from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th. Citigroup restated an “outperform” rating on shares of Benitec Biopharma in a research report on Tuesday, November 4th. Finally, Citizens Jmp lifted their price objective on Benitec Biopharma from $20.00 to $22.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $26.25.

About Benitec Biopharma

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.